EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – RVNCBusiness Wire • 12/13/21
REVANCE THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Revance Therapeutics, Inc. - RVNCPRNewsWire • 12/12/21
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 12/04/21
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmPRNewsWire • 11/26/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law ViolationsNewsfile Corp • 11/26/21
Revance to Present Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Injection Technique at the 2021 American Society for Dermatologic Surgery (ASDS) Virtual Annual MeetingBusiness Wire • 11/19/21
Revance to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ConferenceBusiness Wire • 11/18/21
REVANCE THERAPEUTICS UPDATE Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Revance Therapeutics To Contact Him Directly To Discuss Their OptionsNewsfile Corp • 11/14/21
RVNC INVESTOR ALERT: Hagens Berman Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law ViolationsNewsfile Corp • 11/12/21
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/09/21
Revance Reports Third Quarter 2021 Financial Results, Provides Corporate UpdateBusiness Wire • 11/09/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Revance Therapeutics (RVNC) Investors to Investigation into Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm's Attorneys NowNewsfile Corp • 11/05/21
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 11/03/21
Revance to Release Third Quarter 2021 Financial Results on Tuesday, November 9, 2021Business Wire • 11/02/21
Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 11/01/21
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 11/01/21
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 10/28/21
HAGENS BERMAN, NATIONAL TRIAL ATTOREYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law ViolationsNewsfile Corp • 10/27/21
REVANCE THERAPEUTICS INVESTIGATION: Block & Leviton Is Investigating Revance Therapeutics, Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmNewsfile Corp • 10/26/21
